Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy Please visit their website for more information.
*Proprietary Buy Sell Volume Indicator
| Revenue: $0M |
| Revenue Growth (YOY): nan% |
| Profit (% of Rev): -inf% |
| Income (% of Rev): -inf% |
| Income Growth (YOY): 10.68% |
| Operating Income: $-37M |
| Operating Cash Flow: $-22M |
| Operating Cash Flow Growth (YoY): 11.72% |
| Annual Dividend Yield: 0.00% |
| Total Assets: $938M |
| Total Liabilities: $26M |
| Cash & Equivalent: $50M |
| Total Debt: $1M |
| Debt/Equity: 0.00 |
| Quick Ratio: 36.47 |
| Current Ratio: 36.47 |
| Price/Book: 7.70 |
| Price/Earnings: -70.39 |
| EBITDA: $-37M |
| EPS: -0.22 |
Our proprietary analysis employs a weighted average approach integrating both functional and technical parameters, tailored to the sector, industry, and microeconomic factors. This methodology assigns dynamic weights to the parameters, with a focus on recent trends, ensuring a nuanced evaluation for informed investment decisions. Considering all the above parameters, in addition to some of the derived parameters of the stock in conjunction with its sector and macroeconomic conditions, our proprietary Weighted Average AI model gives a rank of Sell.
TheoryofStocks is not registered as an investment advisor with any regulatory authority. The information provided on this Website is for educational purposes only and should not be construed as financial or investment advice. By continuing to use this site, you are agreeing to the Terms of Use and Privacy Policy. Please read our Disclaimer.
Contact @ support@theoryofstocks.com
© 2024 Stock Articles. All rights reserved.